SCHEMBL31748384

SCHEMBL31748384

COc1ccc(-c2cc3c(-c4noc(=O)[nH]4)c[nH]c3cc2F)cn1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 8/20 0.54
▸ PRKAG1 P54619 3/20 0.47
▸ PRKAA1 Q13131 3/20 0.47
▸ PRKAB1 Q9Y478 3/20 0.47
▸ PRKAB2 O43741 2/20 0.43
▸ PRKAA2 P54646 2/20 0.43
▸ PRKAG3 Q9UGI9 2/20 0.43
▸ PRKAG2 Q9UGJ0 2/20 0.43
▸ PDE3B Q13370 1/20 0.43
▸ PDE3A Q14432 1/20 0.43
▸ MAP3K11 Q16584 1/20 0.37
▸ ERN1 O75460 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ DGAT1 O75907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31748634 0.82 PRKAG1 (0.46) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31748557 0.79 TDO2 (0.39) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31748380 0.78 BTK (0.41) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31748450 0.76 PRKAB2 (0.48) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31748496 0.76 PRKAB2 (0.61) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL25439413 0.76 ALDH1A1 (0.55) ALDH1A1
SCHEMBL31748548 0.76 PRKAB2 (0.41) TDO2PRKAG1PRKAA1PRKAB1PRKAB2
SCHEMBL31748597 0.73 IDO1 (0.38) TDO2
SCHEMBL16990271 0.71 TDO2 (1.00) TDO2PRKAG1PRKAA1PRKAB1
SCHEMBL31748613 0.69 PRKAG1 (0.37) TDO2PRKAG1PRKAA1PRKAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B TDO2 4766/4885PRKAG1 6/4885PRKAA1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback